MDGL Stock Down 10% on Disappointing Preliminary Q4 Rezdiffra SalesZacks Investment Research • 01/15/25
Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on RezdiffraGlobeNewsWire • 01/13/25
Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the marketCNBC • 01/08/25
Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/25
Wall Street Analysts Believe Madrigal (MDGL) Could Rally 26.44%: Here's is How to TradeZacks Investment Research • 11/18/24
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and TheravanceZacks Investment Research • 11/11/24
1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or MoreThe Motley Fool • 11/10/24
Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor ConferencesGlobeNewsWire • 11/06/24
Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European ExpansionSeeking Alpha • 11/03/24
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASHInvestors Business Daily • 11/01/24
Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock UpZacks Investment Research • 11/01/24
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®GlobeNewsWire • 10/30/24
Madrigal Pharmaceuticals: Looking To Finally Establish A Position Around The Q3 EarningsSeeking Alpha • 10/28/24